A
Akebia Therapeutics D
D
AKBA
3.54500
USD
-0.29
(-7.44%)
مغلق
حجم التداول
209,967
الربح لكل سهم
-0
العائد الربحي
-
P/E
-17
حجم السوق
931,044,039
الأخبار المقالات
العنوان: Akebia Therapeutics
القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.